Merrimack Pharmaceuticals/MACK

$14.68

-0.27%
-
1D1W1MYTD1YMAX

About Merrimack Pharmaceuticals

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. The Company is entitled to receive contingent payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. Its payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of ONIVYDE for certain additional clinical indications. ONIVYDE is approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company’s wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.

Ticker

MACK

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Gary Crocker

Employees

-

Headquarters

Cambridge, United States

MACK Metrics

BasicAdvanced
$214.05M
Market cap
-
P/E ratio
-$0.08
EPS
1.45
Beta
-
Dividend rate
$214.05M
1.44663
$15.89
$11.53
119.51K
43.501
-6.05%
-6.22%
-6.22%
11.276
11.418
27.51%

MACK Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-200K
-0%
Profit margin
0%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Merrimack Pharmaceuticals stock?

Merrimack Pharmaceuticals (MACK) has a market cap of $214.05M as of April 14, 2024.

What is the P/E ratio for Merrimack Pharmaceuticals stock?

The price to earnings (P/E) ratio for Merrimack Pharmaceuticals (MACK) stock is 0 as of April 14, 2024.

Does Merrimack Pharmaceuticals stock pay dividends?

No, Merrimack Pharmaceuticals (MACK) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next Merrimack Pharmaceuticals dividend payment date?

Merrimack Pharmaceuticals (MACK) stock does not pay dividends to its shareholders.

What is the beta indicator for Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals (MACK) has a beta rating of 1.45. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Merrimack Pharmaceuticals stock price target?

The target price for Merrimack Pharmaceuticals (MACK) stock is $, which is 100% below the current price of $14.68. This is an average based on projections from analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Merrimack Pharmaceuticals stock

Buy or sell Merrimack Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing